In multiple myeloma, monthly treatment with zoledronic acid beyond two years offers sustained protection against progressive bone disease - Thomas Lund; Michael Tveden Gundesen; Annette Juul Vangsted; Carsten Helleberg; Einar Haukås; Trine Silkjær; Jon Thor Asmussen; Elena Manuela Teodorescu; Bo Amdi Jensen; Tobias Schmidt Slørdahl; Hareth Nahi; Anders Waage; et al. (Blood Cancer Journal, 2024)